IP Library Granted Patent US 9,332,750
Granted Patent B2
US 9,332,750 · App. 14/203,925 · Granted May 10, 2016

Cyclic implant perfusion, cleaning and passivation process and implant produced thereby

Inventors: C. Randal Mills (Alachua, FL); John F. Wironen (Gainesville, FL); Sean Hanstke (Woodbridge, CA)
Assignee: RTI Surgical, Inc.
A01N1/0289A61L2/0088A61L2/025
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,332,750
App. No.
14/203,925
Granted
May 10, 2016
Kind
B2
Abstract

This invention is a novel method for perfusion of a porous implant which achieves efficient interpenetration of desired factors into and removal of undesirable factors from the pores of the implant, cleaning of the implant, efficient passivation of the implant (inactivation of pathogens, microorganisms, cells, viruses and the like and reduction in antigenicity thereof), and the novel implant produced by such treatment. The process presents a system wherein the rate of pressure cycling, the fact of pressure cycling, and the amplitude of pressure cycling, results in highly cleaned tissues and other implants for implantation. Target decontamination goals for this process include between about a one (1) to twelve (12) log reduction in bacterial contamination, between about a one (1) to fifteen (15) log reduction in enveloped virus contamination, up to about a five (5) log reduction in non-enveloped virus contamination, between about a two (2) to ten (10) fold reduction in endotoxin, maintenance of implant or graft biologic and biomechanical properties, absence of tissue toxicity due to cleaning solutions used, and reduced implant antigenicity.

Claims (18)

1. A method for producing a cleaned allograft or xenograft tissue implant by perfusion of cleaning solutions comprising:

machine dimensioning an allograft or xenograft tissue implant to achieve final implant dimensions;

placing said implant in a sealed vessel; and

exposing said implant to three or more different cleaning solutions in series;

wherein said three or more different cleaning solutions comprise, respectively:

a) a detergent solution; b) a water-miscible alcohol; and c) a hydrogen peroxide solution; and further wherein oscillating fluid pressure is used during at least a part of said exposing step.

2. The method of claim 1 , wherein the implant produced is suitable for implantation or processing for implantation in humans.

3. The method of claim 1 , wherein said tissue comprises at least one of the following: cortical bone, cancellous bone, fascia, whole joint, tendon, ligament, dura, pericardia, heart valve, vein, neural tissue, submucosal tissue, cartilage, or combinations thereof.

4. The method of claim 3 , wherein said tissue comprises at least one of the following: cortical bone or cancellous bone, or combinations thereof.

5. The method of claim 3 , wherein said tissue comprises at least one of the following: fascia, whole joint, tendon, ligament, dura, pericardia, heart valve, vein, neural tissue, submucosal tissue, or cartilage, or combinations thereof.

6. The method of claim 1 , wherein said implant is made from tissue derived from a single donor.

7. The method of claim 1 , wherein said implant is made from tissue derived from a pool of donor tissues.

8. The method of claim 1 , further comprising placing said cleaned tissue implant into a sterile, sealable package.

9. The method of claim 8 , further comprising performing a surface decontamination step prior to sealing said package.

10. The method of claim 1 , wherein the implant is perfused or coated with a bioactive substance.

11. The method of claim 10 , wherein said bioactive substance is a drug or a growth factor.

12. The method of claim 11 , wherein said growth factor is a bone morphogenetic protein, tissue growth factor beta or a member of the tissue growth factor beta family of growth factors, cartilage-derived morphogenetic proteins I or II or both, a cartilage derived growth factor, an angiogenic factor, or platelet derived growth factor.

13. The method of claim 1 , further comprising maintaining the temperature between about 35-40 degrees centigrade during the exposing step.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Jul 21, 2020
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: RTI SURGICAL, INC.; PIONEER SURGICAL TECHNOLOGY, INC.; TUTOGEN MEDICAL, INC.
Reel/Frame 053260/0398 →
RELEASE OF SECURITY INTEREST Recorded Jul 20, 2020
From: ARES CAPITAL CORPORATION, AS AGENT
To: RTI SURGICAL, INC.; PIONEER SURGICAL TECHNOLOGY, INC.; TUTOGEN MEDICAL, INC.; PARADIGM SPINE, LLC; FOURTH DIMENSION SPINE, LLC
Reel/Frame 053257/0652 →
SECURITY INTEREST Recorded Mar 8, 2019
From: RTI SURGICAL, INC.; PIONEER SURGICAL TECHNOLOGY, INC.; TUTOGEN MEDICAL, INC.; PARADIGM SPINE, LLC; FOURTH DIMENSION SPINE, LLC
To: ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 048543/0505 →
RELEASE OF SECURITY INTEREST Recorded Jun 7, 2018
From: TD BANK, N.A., AS ADMINISTRATIVE AGENT
To: RTI SURGICAL, INC.
Reel/Frame 046327/0864 →
SECURITY INTEREST Recorded Jun 6, 2018
From: RTI SURGICAL, INC.; PIONEER SURGICAL TECHNOLOGY, INC.; TUTOGEN MEDICAL, INC.
To: JPMORGAN CHASE BANK, N.A., AS THE ADMINISTRATIVE AGENT
Reel/Frame 046303/0926 →
SECURITY INTEREST Recorded Aug 20, 2017
From: RTI SURGICAL, INC.
To: TD BANK, N.A.
Reel/Frame 043608/0874 →
Continuity (6)
Continuation 13399734 · Feb 17, 2012
Continuation 12389124 · Feb 19, 2009
Continuation 10980661 · Nov 2, 2004
Continuation 10192180 · Jul 10, 2002
Division 09191232 · Nov 13, 1998
Related Publication 20140193798A1 · Jul 10, 2014